Colgate-Palmolive Company (CL) is a global leader in oral care, personal care, home cleaning and pet nutrition products, with a heritage dating back to 1806. Headquartered in New York City, it operates in over 200 markets worldwide. Colgate’s market cap of around $76.6 billion reflects its status as a large-cap stalwart in the consumer staples space.
Companies with a market cap of $10 billion or more are generally classified as “large-cap” stocks, and Colgate-Palmolive Company comfortably fits into this category. The global consumer-staples giant has built a dominant presence in everyday household and personal care products, particularly in oral care.
Its stock had reached a 52-week high of $100.18 in March 2025, and is down about 4.7% from that level. Colgate’s stock has surged by 22.1% over the past three months, while the broader Nasdaq Composite ($NASX) has declined around 4%.
Over the past 52 weeks, Colgate’s stock has gained 2.9%, and on a year-to-date (YTD) basis, it rose 20.9%. On the other hand, the NASX gained 22.7% over the past year but slumped 3.1% this year.
The stock is currently trading well above its 50-day and 200-day moving averages, indicating significant momentum.
Colgate-Palmolive Company stock is rising largely due to strong earnings momentum and improving investor sentiment following its latest quarterly results. The company reported Q4 revenue of about $5.2 billion, representing 5.8% year-over-year growth, while adjusted EPS came in at $0.95, up from $0.91 a year earlier, beating Wall Street expectations and signaling steady demand for essential consumer products.
Comparing Colgate’s performance with Kimberly-Clark Corporation (KMB), which has dropped 27% over the past 52 weeks but gained 3.7% this year, Colgate is the clear outperformer here.
Wall Street analysts are moderately bullish on Colgate’s stock. The stock has a consensus rating of “Moderate Buy” from the 21 analysts covering it. The mean price target of $96.05 indicates a slight upside compared to current levels, while the Street-high price target of $105 indicates a 9.9% upside.
